Gilsiane de Sousa Sampaio

Gilsiane de Sousa Sampaio

Auto-generated profile, based on publicly available information

Gilsiane de Sousa Sampaio

Universidade de Rio Verde, Brazil

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Geriatrics Gerontology and Aging
Verified
Journal Article
Closed access
FMFrancelle Adorno Sôffa Guimarães Monteiro
Francelle Adorno Sôffa Guimarães Monteiro
GPGabriela Mesquita Pontes
Gabriela Mesquita Pontes
GSGilsiane de Sousa Sampaio
Gilsiane de Sousa Sampaio
MOMaria Eugênia Ribeiro Carvalho de Oliveira
Maria Eugênia Ribeiro Carvalho de Oliveira
PLPaulo Marcelo de Andrade Lima
Paulo Marcelo de Andrade Lima
Objective: To describe the safety of medicines available in the “Brazilian List of Essential Medicines” (RENAME/2022) for the main comorbidities that affect older persons according to the Beers criteria 2019. Methods: Medicines listed in RENAME and recommended by the respective Brazilian medical guidelines for the treatment of hypertension, heart failure, diabetes, and neurological/ psychiatric diseases were evaluated for their safety profiles according to the Beers criteria 2019. Results: Fifty-eight out of 529 medicines in RENAME were evaluated. Of these, 29 were included in any of the Beers criteria: 20 were classified as potentially inappropriate, 17 should be avoided due to disease exacerbation, and 14 needed to be used with caution. Considering drugs used to treat cardiovascular, diabetes, and neurological/psychiatric disorders, 40.00, 37.50 and 60.00% respectively, had some criterion for their appropriate use in older persons. Conclusion: RENAME presents alternatives for the safe treatment of older patients. In the treatment of cardiovascular diseases, diabetes, and neurodegenerative diseases, the firstchoice recommendations are available in RENAME. Regarding psychiatric disorders, safe pharmacological alternatives are still scarce and need to be better discussed.